Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

As a new class of antidiabetic drug, incretin-based therapies, which include dipeptidyl peptidase-4 inhibitors (DPP-4Is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have raised concerns about symptoms of withdrawal in patients with type 2 diabetes mellitus (T2DM), such as dizziness an...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Aging Dis
Prif Awduron: Gao, Le, Yu, Shuqing, Cipriani, Andrea, Wu, Shanshan, Huang, Yi, Zhang, Zilu, Yang, Jun, Sun, Yixin, Yang, Zhirong, Chai, Sanbao, Zhang, Yuan, Ji, Linong, Zhan, Siyan, Sun, Feng
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: JKL International LLC 2019
Pynciau:
Review
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6844583/
https://ncbi.nlm.nih.gov/pubmed/31788342
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14336/AD.2019.0303
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg